Physician profile
Brandon M Harnos
NPI 1942856257
$6,831.86
in general payments reported to CMS, 2019-2025
14 companies · $3,412 in 2025
The $3,412 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.22 · 2020: $35.39 · 2021: $453 · 2022: $372 · 2023: $701 · 2024: $1,793 · 2025: $3,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Food and Beverage: $2,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Food and Beverage | $2,656.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,869.76 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $2,588.48 | 2021-2025 | Precision 1, Air Optix Color, Dailies Total1 |
| Horizon Therapeutics Plc | $249.37 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $212.09 | 2024-2025 | Xdemvy |
| Coopervision INC. | $189.22 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $146.37 | 2025 | |
| Kala Pharmaceuticals, INC. | $143.85 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $107.74 | 2021-2025 | |
| Dompe US, INC. | $100.00 | 2023 | Oxervate |
| Sun Pharmaceutical Industries INC. | $71.72 | 2020-2025 | |
| Optos, INC. | $65.22 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.97 | 2021-2022 | |
| Allergan, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Harnos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.